Retatrutide

Retatrutide is a highly advanced investigational peptide that functions as a triple hormone receptor agonist, simultaneously activating GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This unique mechanism positions it at the forefront of metabolic and obesity research.

Unlike traditional peptides that target a single pathway, Retatrutide enhances energy expenditure, suppresses appetite, and improves glucose metabolism through a multi-pathway approach. This makes it a promising candidate for research into obesity, type 2 diabetes, and metabolic disorders.

Researchers have shown significant interest in Retatrutide due to its potential to deliver greater weight reduction and metabolic improvements compared to earlier-generation peptides. Its combined action helps regulate hunger signals, increase fat oxidation, and support overall metabolic efficiency.

Retatrutide is commonly studied in advanced metabolic research settings and is considered one of the most innovative peptides in the field of weight management science.

Key Benefits:

• Triple agonist action (GLP-1, GIP, glucagon receptors)
• Supports significant weight loss and fat reduction research
• Enhances metabolic rate and energy expenditure
• Improves glucose control and insulin sensitivity
• Helps regulate appetite and satiety

Product Specifications:

• Peptide Name: Retatrutide
• Purity: ≥98%
• Form: Lyophilized powder
• Dosage: 10mg per vial (customizable)
• Storage: Store at -20°C (refrigerated after reconstitution)
• Intended Use: Research purposes only